Centers | ||
Drug Discovery Unit | Edinburgh Drug Discovery | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
The Drug Discovery Unit (DDU) is a fully integrated drug discovery group established to translate world-class biology research into novel drug targets and candidate drugs. Housed within purpose built facilities at the University of Dundee, the DDU... Read more |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
Research collaboration and license agreementThe University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson’s disease. This announcement builds upon... View all Research Collaboration and license agreementThe Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in several forms of neurodegeneration, including... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |


